Plaque Psoriasis 
The MD Magazine Plaque Psoriasis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

Psoriasis Patients Covered by Medicare Are More Likely to Discontinue Biologic Drug Therapy
Nearly 50% of Medicare patients taking biologic therapies for moderate-to-severe plaque psoriasis stop treatment within a year, reported a study by the Perelman School of Medicine at the University of Pennsylvania.
Researchers have concluded that there is a small but significant genetic component to the observed connection between high body mass index (BMI) and psoriasis.
A new study has uncovered a potential shared genetic source between psoriasis and obesity, which could also address a connection among psoriasis, type 2 diabetes, and body mass index (BMI).
The FDA has approved Inflectra (infliximab-dyyb/Celltrion, Inc), the biosimilar for Remicade (infliximab) for the treatment of patients suffering from serious autoimmune diseases.
Men afflicted with psoriasis are more likely to suffer from erectile dysfunction.
The FDA has approved ixekizumab (Taltz/Eli Lilly) for moderate to severe plaque psoriasis. It is administered by injection.
Researchers have discovered new Lyme disease-causing bacteria, Borrelia mayonii (B. mayonii) in the upper Midwest. Infection may trigger nausea, vomiting, and a more widespread rash, officials say.
Researchers are closing in on a medical treatment for wart-like skin growths know as seborrheic keratosis.
Age matters when it comes to patients’ access to psoriasis treatment.

Most Popular


$vacMongoViewPlus$ $vAR$